Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

161. Pilot study of a smartphone application designed to socially motivate cardiovascular disease patients to improve medication adherence Full Text available with Trip Pro

Pilot study of a smartphone application designed to socially motivate cardiovascular disease patients to improve medication adherence Social support received by patients from family and community has been identified as a key factor for success in improving medication adherence in those patients. This pilot study aimed to investigate the usability and feasibility of PillPal, a smartphone application that uses video-chatting as a social motivation medium to encourage medication adherence (...) in cardiovascular disease (CVD) patients. We additionally gathered feedback on the Physician Calendar, an accompanying web platform that allows clinicians to view patient adherence data generated from the app.Thirty patients were recruited from the Johns Hopkins Hospital (JHH) Lipid Clinic (n=14) and Inpatient Cardiology Service (n=16) to pilot test the app. Data were obtained through in-person interviews in which patients tested out the app and answered standardized questions regarding the app's feasibility

2018 mHealth

162. Primary care: Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Full Text available with Trip Pro

Primary care: Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Article Text Commentary Primary care Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Jonathan Mant Statistics from Altmetric.com Commentary on: Anand SS, Bosch J, Eikelboom JW, et al

2018 Evidence-Based Medicine

163. Primary care: Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research

Primary care: Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research Article Text Commentary Primary care Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research Dexter Canoy , Kazem Rahimi Statistics from

2018 Evidence-Based Medicine

164. Xarelto - rivaroxaban - Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.

Criteria 1 : For use in combination with low-dose ASA, for the prevention of stroke, myocardial infarction and cardiovascular death in patients with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD). Submission Type: New Indication Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: November 20, 2018 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule B The requested reimbursement criteria (...) Xarelto - rivaroxaban - Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. rivaroxaban | CADTH.ca Find the information you need rivaroxaban rivaroxaban Last Updated: December 7, 2018 Result type: Reports Project Number: SR0569-000 Product Line: Generic Name: rivaroxaban Brand Name: Xarelto Manufacturer: Bayer Inc. Indications: Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. Manufacturer Requested Reimbursement

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

165. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. Full Text available with Trip Pro

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with myocardial fibrosis and renin-angiotensin system upregulation, potentially providing prognostic information distinct from standard cardiovascular (CV) biomarkers.To evaluate the association of FGF-23 with recurrent CV events in patients (...) after an acute coronary syndrome (ACS).C-terminal FGF-23 was measured in plasma samples using an established enzyme-linked immunosorbent assay system for 4947 patients within 30 days of ACS (median, 14 days) and with 1 additional CV risk factor in the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial of the lipoprotein-associated phospholipase A2 inhibitor darapladib vs placebo performed from December 1, 2009, to April 24, 2014 (median follow-up

2018 JAMA cardiology Controlled trial quality: predicted high

166. ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study. Full Text available with Trip Pro

, double-blind, placebo-controlled phase 3 trial conducted in patients with high-risk vascular disease randomized from October 2012 through December 2013. The genotyping was conducted from January 2017 to March 2017, and the data analyses were conducted from July 2017 to November 2017.Evacetrapib, 130 mg, or matching placebo.The primary analyses used a conditional logistic regression model to assess the odds ratio (OR) for major adverse cardiovascular events for evacetrapib compared with placebo (...) ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study. A pharmacogenetic analysis of dalcetrapib, a cholesteryl ester transfer protein inhibitor, reported an association between a single-nucleotide polymorphism (SNP) in the ADCY9 gene (rs1967309) and reduction in major adverse cardiovascular events despite a neutral result for the overall trial.To determine whether the association between the SNP in the ADCY9

2018 JAMA cardiology Controlled trial quality: predicted high

167. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. Full Text available with Trip Pro

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. An elevated level of urinary albumin to creatinine ratio (UACR) is a marker of renal dysfunction and predictor of kidney failure/death in patients with type 2 diabetes. The prognostic use of UACR in established cardiac biomarkers is not well described.To evaluate whether UACR offers incremental prognostic benefit beyond (...) risk factors and established plasma cardiovascular biomarkers.The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study was performed from May 2010 to May 2013 and evaluated the safety of saxagliptin vs placebo in patients with type 2 diabetes with overt cardiovascular disease or multiple risk factors. Median follow-up was 2.1 years (interquartile range, 1.8-2.3 years).Patients were randomized

2018 JAMA cardiology Controlled trial quality: predicted high

168. Diabetic cardiovascular disease

Diabetic cardiovascular disease Diabetic cardiovascular disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Diabetic cardiovascular disease Last reviewed: February 2019 Last updated: March 2018 Summary Cardiovascular disease (CVD) and stroke account for about two-thirds of deaths in people with diabetes. People with diabetes have a 2- to 4-fold increased risk of CVD and are up to 3 times more likely to die after (...) ://care.diabetesjournals.org/content/41/Supplement_1 http://www.ncbi.nlm.nih.gov/pubmed/29222372?tool=bestpractice.com Diabetes is an established major risk factor for the development of cardiovascular disease, including coronary artery disease (CAD), cerebrovascular disease (stroke or transient ischaemic attack [TIA]), and peripheral arterial disease. This monograph will discuss CAD in greatest detail. History and exam presence of risk factors chest pain dyspnoea on exertion hypotension rales S3 gallop BP >140/90 mmHg

2018 BMJ Best Practice

169. Primary prevention of cardiovascular disease

Primary prevention of cardiovascular disease Prescrire IN ENGLISH - Spotlight ''Primary prevention of cardiovascular disease '', 1 January 2018 {1} {1} {1} | | > > > Primary prevention of cardiovascular disease Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the January issue of Prescrire International: Primary prevention of cardiovascular (...) disease FREE DOWNLOAD This month's sample page from the Reviews section makes the point that statins and hypotensive drugs ought not necessarily to be prescribed for everyone who may be at risk. Full text available for free download. Summary In a large-scale placebo-controlled tria l, about 13 000 patients at risk of a first cardiovascular event were followed for approximately six years. Low-dose rosuvastatin and the combination of candesartan + hydrochlorothiazide did not reduce total mortality

2018 Prescrire

170. Dietary fats and cardiovascular disease

, Szeto IM, Smit G, et al. Cheese Consumption and Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Studies. Eur J Nutr. 2016 36. Raziani F, Tholstrup T, Kristensen MD, Svanegaard ML, Ritz C, et al. High Intake of Regular-Fat Cheese Compared with Reduced-Fat Cheese Does Not Affect Ldl Cholesterol or Risk Markers of the Metabolic Syndrome: A Randomized Controlled Trial. Am J Clin Nutr. 2016;104(4):973-81. 37. Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, et al. Added Sugar Intake (...) Dietary fats and cardiovascular disease Dietary fats and cardiovascular disease An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation. September 2017 2 DIETARY FATS AND CARDIOVASCULAR DISEASE OUTCOMES | SAX INSTITUTE An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation. March 2017. This report was prepared by: Professor Peter Clifton and Dr Jennifer Keogh University of South Australia September 2017 © Sax

2018 Sax Institute Evidence Check

171. Dietary patterns and cardiovascular disease outcomes

of CVD, the Portfolio diet, followed by the DASH and weight loss/calorie-restricted diet is recommended. However, this is dependent on the pre-existing condition. In groups both with and without CVD, the most consistent evidence was found for the DASH pattern with adherence resulting in improvements in blood pressure, blood lipids and body weight. DIETARY PATTERNS AND CARDIOVASCULAR DISEASE OUTCOMES | SAX INSTITUTE 7 2 Background Various dietary components have been evidenced as important modifiable (...) Dietary patterns and cardiovascular disease outcomes An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation of Australia. April 2017. Dietary Patterns and Cardiovascular Disease Outcomes An Evidence Check rapid review brokered by the Sax Institute for the National Heart Foundation of Australia. April 2017. This report was prepared by: Clare Collins, Tracy Burrows, Megan Rollo. University of Newcastle April 2017 © Sax Institute 2017 This work is copyright

2018 Sax Institute Evidence Check

172. Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings Full Text available with Trip Pro

Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings The Community Preventive Services Task Force recommended five interventions for cardiovascular disease prevention between 2012 and 2015. Systematic economic reviews of these interventions faced challenges that made it difficult to generate meaningful policy and programmatic conclusions. This paper describes the methods used to assess, synthesize, and evaluate the economic evidence

2018 EvidenceUpdates

173. Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols

Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Technical package for cardiovascular disease management in primary health care: evidence-based (...) treatment protocols View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization . (‎2018)‎. Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 41 p. Gov't Doc # WHO/NMH/NVI/18.2 Other Language Versions Collections Language English Metadata Related items Showing items related by title and MeSH subject.  Organisation mondiale de la Santé (‎ WHO

2018 WHO

174. Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling

Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling (...) View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization . (‎2018)‎. Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 28 p. Gov't Doc # WHO/NMH/NVI/18.1 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Assembly, 65 (‎ A65/6 Add.1 , 2012 )‎  World Health Organization

2018 WHO

175. Technical package for cardiovascular disease management in primary health care: systems for monitoring

Technical package for cardiovascular disease management in primary health care: systems for monitoring Technical package for cardiovascular disease management in primary health care: systems for monitoring JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Technical package for cardiovascular disease management in primary health care: systems for monitoring View/ Open Rights View (...) Statistics Altmetrics Share Citation World Health Organization . (‎2018)‎. Technical package for cardiovascular disease management in primary health care: systems for monitoring. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 29 p. Gov't Doc # WHO/NMH/NVI/18.5 Other Language Versions Collections Language English Metadata Related items Showing items related by title and MeSH subject.  منظمة الصحة العالمية (‎ 1978 )‎  Organisation mondiale de la Santé ; Mahler, Halfdan (‎ 1978

2018 WHO

176. Technical package for cardiovascular disease management in primary health care: team-based care

Technical package for cardiovascular disease management in primary health care: team-based care Technical package for cardiovascular disease management in primary health care: team-based care JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Technical package for cardiovascular disease management in primary health care: team-based care View/ Open Rights View Statistics (...) Altmetrics Share Citation World Health Organization . (‎2018)‎. Technical package for cardiovascular disease management in primary health care: team-based care. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 34 p. Gov't Doc # WHO/NMH/NVI/18.4 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  منظمة الصحة العالمية (‎ 1978 )‎  Organisation mondiale de la Santé ; Mahler, Halfdan (‎ 1978 )‎ 239 p.  World Health Organization ; Mahler

2018 WHO

177. Cardiovascular Disease: Risk Assessment With Nontraditional Risk Factors

Cardiovascular Disease: Risk Assessment With Nontraditional Risk Factors Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adding the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, or coronary artery calcium (CAC) score to traditional risk assessment for cardiovascular (...) benefits and harms. Importance Cardiovascular disease is the most common cause of death among adults in the United States. Treatment to prevent CVD events by modifying risk factors is currently informed by the Framingham Risk Score, the Pooled Cohort Equations, or similar CVD risk assessment models. If current CVD risk assessment models could be improved by adding more risk factors, treatment might be better targeted, thereby maximizing the benefits and minimizing the harms. Detection The USPSTF found

2018 U.S. Preventive Services Task Force

178. Peripheral Artery Disease and Cardiovascular Disease: Screening and Risk Assessment With the Ankle-Brachial Index

Peripheral Artery Disease and Cardiovascular Disease: Screening and Risk Assessment With the Ankle-Brachial Index Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for peripheral artery disease (PAD) and cardiovascular disease (CVD) risk with the ankle-brachial index (ABI) in asymptomatic adults (...) , in addition to isolating the effect of individual tests, should address the population of persons at potentially increased risk for PAD who are not already receiving interventions to reduce cardiovascular risk, because this is the population most likely to benefit from an additional screening intervention. Studies of screening with the ABI and interventions to stop disease progression in the lower limbs in more diverse populations (eg, women, racial/ethnic minorities, or persons with a lower socioeconomic

2018 U.S. Preventive Services Task Force

179. Cardiovascular Disease Risk: Screening With Electrocardiography

in addition to the evidence of clinical benefits and harms. Importance Cardiovascular disease, which encompasses atherosclerotic conditions such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease, is the most common cause of death among adults in the United States. Treatment to prevent CVD events by modifying risk factors is currently informed by CVD risk assessment with tools such as the Framingham Risk Score or the Pooled Cohort Equations, which stratify individual risk (...) to additional testing and treatment. Studies that measure risk reclassification should report total, event, and nonevent Net Reclassification Indices, with corresponding confidence intervals, as well as measures of calibration and discrimination. Burden of Disease Cardiovascular disease is the most common cause of death among adults in the United States, accounting for 1 in 3 deaths. Although CVD remains a significant cause of illness and death, mortality from CVD has been decreasing over time in the United

2018 U.S. Preventive Services Task Force

180. Predicting effective factors on eating behaviors in the prevention of cardiovascular disease based on the PRECEDE model Full Text available with Trip Pro

Predicting effective factors on eating behaviors in the prevention of cardiovascular disease based on the PRECEDE model Changes in eating behavior can reduce the risk of developing cardiovascular disease. The aim of this study was to predict the effective factors of eating behaviors in the prevention of cardiovascular disease using the PRECEDE model.This cross-sectional study was performed on 400 subjects aged from 20 to 60 years old in Kerman, Iran in 2016. The participants were selected using (...) ). Perceived self-efficacy had the most, and reinforcing factors the least correlation with eating behavior.According to the results of this study, self-efficacy, attitude, and enabling factors were the main predicting factors for eating behaviors; therefore, to prevent cardiovascular disease and enhance healthy eating behavior, it is recommended to change attitude, and enhance self-efficacy and enabling factors in the community.

2017 Electronic physician